CAR T-Cell survivors: what happens years later?
NCT ID NCT07048535
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 30 times
Summary
This study follows 80 children and young adults who received CAR T-cell therapy for B-cell acute lymphoblastic leukemia (B-ALL) at least two years ago. Researchers want to see how feasible it is to track their long-term health, including any new or lasting side effects, brain function, immune health, and quality of life. Participants must be in remission and have had no other treatments after CAR T-cells (except a stem cell transplant). The goal is to better understand the lasting effects of this therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
St. Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD19-directed CAR T-cell therapy
What this could lead to
If successful, this study could reveal the long-term health outcomes and quality of life after CAR T-cell therapy, helping doctors better manage survivors.
What could go wrong
This is an observational follow-up study, not a treatment trial. It may not lead to new therapies, and results depend on participant willingness to return for assessments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.